Article Text

Download PDFPDF
Letter
Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

Statistics from Altmetric.com

Footnotes

  • Contributors TPZ, STE and PJN planned the study. All authors contributed to data acquisition. TPZ, SMZ and PJN analysed the data. TPZ wrote the first draft; all authors revised the draft paper. TPZ submitted the study and is responsible for the overall content as guarantor.

  • Funding AZ has received speaker fees from Boehringer-Ingelheim and consulting fees from Medtronic. PM has received through his institution (CHUV) within the last 3 years: research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and Cardiomet-CHUV; speaker fees from Bayer, Boehringer-Ingelheim, Covidien and St. Jude Medical; honoraria from scientific advisory boards from Boehringer-Ingelheim, Bayer, Pfizer; consulting fees from Pierre-Fabre. He also has received travel support from Boehringer-Ingelheim and Bayer. He uses all this support for stroke education and research. YB served on scientific advisory boards or received speaker honoraria for Boehringer-Ingelheim France, AstraZeneca, Daiichi-Sankyo, BMS, Pfizer, MSD, and Bayer. MA received honoraria for giving lectures and serving on advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien. D.L. participated during the last five years to advisory boards, symposia or trials sponsored by Sanofi Aventis, BMS, AstraZeneca, Boehringer-Ingelheim, Servier, Ebewe, CoLucid Pharm, Brainsgate, Photothera, Lundbeck, GSK, Bayer, Pfizer, and Allergan (honorarium paid to Adrinord or research account of the hospital) and was an associated editor of the Journal of Neurology, Neurosurgery and Psychiatry 2004-2010 (personal financial compensation). P.R. received speaker honoraria (<10.000€ / 2 years) from Boehringer Ingelheim. TT: Research contracts with Boehringer-Ingelheim, BrainsGate, Pfizer, and Bayer. Advisory board memberships: Boehringer-Ingelheim, Medfield Diagnostics, Pfizer, and Bayer. CHN. has received [through his institution (Charité)] within the last three years: research grants from German Ministry of research and education, and received funding for travel or speaker honoraria from Bayer, Boehringer Ingelheim, BMS/Pfizer, and Sanofi. STE has received funding for travel or speaker honoraria from Bayer and Boehringer Ingelheim, he has served on scientific advisory boards for Bayer, Boehringer Ingelheim, BMS/Pfizer, and Covidien and on the editorial board of Stroke. He has received an educational grant from Pfizer and research support from the Science Funds [Wissenschaftsfonds] of the University Hospital Basel, the Swiss Heart Foundation, and the Swiss National Science Foundation. PJN has received consulting fees from Boehringer Ingelheim.

  • Competing interests None declared.

  • Ethics approval Approval was obtained from ethical committees in each participating centre.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Collaborators TRISP collaborators are listed in a supplementary file.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.